Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Walgreens Boots Alliance : Pharmacy chains failed to prevent opioid misuse, U.S. jury hears

10/04/2021 | 06:54pm EST
FILE PHOTO: People are inoculated against the coronavirus disease (COVID-19) at a Walgreens store in Chicago

CLEVELAND (Reuters) - Pharmacy operators including CVS Health Corp and Walmart Inc fueled the U.S. opioid epidemic by failing to stop massive quantities of addictive painkillers from reaching the black market, a lawyer for two Ohio counties said at the start of a trial on Monday.

Mark Lanier told a federal jury in Cleveland hearing the first trial the pharmacy chains have faced in nationwide litigation over the epidemic that the companies bore responsibility for drug abuse in the counties of Lake and Trumbull.

"They just dispensed like a vending machine," Lanier said in his opening statement.

He said the four pharmacy operators now on trial, who also include Walgreens Boots Alliance Inc and Giant Eagle Inc, were "the last line of defense" against people obtaining pills to illicitly sell on the streets.

Lanier said the companies did not employ enough pharmacists to do the job right, failed to identify "red flags" of misuse and prioritized filling prescriptions quickly while patients shopped at their retail stores.

"From the very beginning, they were supposed to train their pharmacists, and they didn't," Lanier said. "From the very beginning, they should have given the pharmacists the tools they'd need and they didn't."

Kaspar Stoffelmayr, a lawyer for Walgreens, countered that others were to blame for the surge in pain pills, including doctors who prescribed them and regulators who saw pain as needing vital treatment.

"Pharmacists don't create demands," he said. "They don't tell doctors what prescriptions to write."

Most instances of opioids being diverted for illicit uses did not involve pharmacies, Stoffelmayr said. He cited a study showing that most prescribed pain pills go unused and sit in medicine cabinets. "A lot of them end up in wrong hands."

Opening statements will continue on Tuesday with arguments from the other companies. They deny wrongdoing, saying criminals were more likely to obtain opioids illegally from other sources, including pill mills, crooked doctors and drug traffickers.

More than 3,300 cases have been brought largely by state and local governments seeking to hold the companies responsible for an opioid abuse epidemic that U.S. government data shows led to nearly 500,000 overdose deaths from 1999 to 2019.

The pharmacy operators have never faced trial before in the litigation.

Should jurors find the companies created a public nuisance, U.S. District Judge Dan Polster will determine how much they must pay to abate, or address, the health crisis in the communities. He has urged the parties to settle.

The trial comes after the three largest U.S. distributors that supply pharmacies - McKesson Corp, Cardinal Health Inc and AmerisourceBergen Corp - and the drugmaker Johnson & Johnson in July proposed paying up to $26 billion to settle cases against them.

A bankruptcy judge in August approved a settlement by OxyContin maker Purdue Pharma LP and its wealthy Sackler family owners that the company values at more than $10 billion.

(Reporting by Grant Segall in Cleveland and Nate Raymond in Boston; Editing by Noeleen Walder and Bill Berkrot)

By Grant Segall

ę Reuters 2021
10:52aWALGREENS BOOTS ALLIANCE : 2021 Annual Report
10:52aWALGREENS BOOTS ALLIANCE : 2022 Proxy Statement
08:02aWalgreens Boots Alliance Schedules Fiscal 2022 First Quarter Earnings Announcement for ..
12/07Elizabeth Holmes denies misleading investors in trial testimony
12/07Elizabeth Holmes to resume testimony as fraud trial nears end
12/06Walgreens and Mental Health America Team Up to Raise Funds and Provide Mental Health Su..
12/06Walgreens Boots Alliance Reportedly Said to Be Considering Sale of UK Unit
12/03Walgreens Explores Options for British Retail Chain Boots
12/03NORTH AMERICAN MORNING BRIEFING : Oil Rises, Stock Futures Waver as Markets Cap Volatile W..
12/03Walgreens Boots Alliance Reportedly to Explore Sale of the Business
More news
Analyst Recommendations on WALGREENS BOOTS ALLIANCE, INC.
More recommendations
Financials (USD)
Sales 2022 131 B - -
Net income 2022 3 328 M - -
Net Debt 2022 9 302 M - -
P/E ratio 2022 12,7x
Yield 2022 4,00%
Capitalization 41 901 M 41 901 M -
EV / Sales 2022 0,39x
EV / Sales 2023 0,36x
Nbr of Employees 258 500
Free-Float 61,1%
Duration : Period :
Walgreens Boots Alliance, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WALGREENS BOOTS ALLIANCE, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 22
Last Close Price 48,50 $
Average target price 53,81 $
Spread / Average Target 10,9%
EPS Revisions
Managers and Directors
Rosalind Gates Brewer Chief Executive Officer & Director
John Standley President & Executive Vice President
James Kehoe Global Chief Financial Officer & Executive VP
Stefano Pessina Executive Chairman
Francesco Tinto Global Chief Information Officer & Senior VP
Sector and Competitors